Lazertinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 240 mg, 80 mg
Reference Brands: Lazcluze (USA)
Category: Oncology Cancer Care
Lazertinib is a third‑generation EGFR tyrosine kinase inhibitor used to treat advanced or metastatic non‑small cell lung cancer (NSCLC) in adults whose tumors carry certain EGFR mutations (exon 19 deletions or exon 21 L858R substitution). It blocks abnormal EGFR signaling in cancer cells, inhibiting growth and helping shrink tumors. Lazertinib is available in Tablets and strengths such as 240 mg, 80 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Lazertinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Lazertinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Lazertinib is used for the treatment of advanced or metastatic Non‑Small Cell Lung Cancer (NSCLC) in adult patients whose tumors have specific mutations in the Epidermal Growth Factor Receptor (EGFR) gene, such as exon 19 deletion or exon 21 L858R substitution. It is often prescribed in combination with Amivantamab as a first‑line chemotherapy‑free regimen for eligible patients.
Lazertinib is a small‑molecule EGFR tyrosine kinase inhibitor. It selectively and irreversibly binds to mutant EGFR proteins in cancer cells, blocking signals that promote tumor cell proliferation and survival. It is formulated with excipients suitable for oral administration.
The trade names for lazertinib include Lazcluze and Leclaza (region-specific).
Lazcluze (lazertinib) is manufactured by Janssen-Cilag, part of Johnson & Johnson.
The generic name is lazertinib.
Brand names include Lazcluze and Leclaza.
Lazertinib is manufactured in GMP-certified facilities by Janssen-Cilag for global distribution.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
